Latest Ratios: P/E Ratio 62.5x · EV/EBITDA 32.5x · ROE 9.0%. (1997–2026 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $11.4B | $11.1B | $8.2B | $11.5B | $13.2B | $14.2B | $18.2B | $10.4B | $8.1B | $5.6B | $4.4B |
| Enterprise Value | $11.4B | $11.1B | $8.5B | $11.8B | $13.5B | $14.4B | $18.5B | $10.7B | $8.5B | $5.8B | $4.7B |
| P/E Ratio → | 62.52 | 60.91 | 111.85 | 68.24 | 46.38 | 52.20 | 129.39 | 45.53 | 84.06 | 45.11 | 56.50 |
| P/S Ratio | 9.34 | 9.13 | 6.74 | 9.94 | 11.62 | 12.86 | 19.58 | 14.09 | 11.36 | 8.76 | 7.83 |
| P/B Ratio | 5.35 | 5.21 | 4.28 | 5.57 | 6.72 | 8.36 | 11.60 | 7.53 | 6.96 | 5.22 | 4.63 |
| P/FCF | 43.14 | 42.14 | 32.03 | 48.79 | 61.13 | 50.73 | 59.21 | 67.80 | 51.91 | 37.68 | 34.36 |
| P/OCF | 38.88 | 37.98 | 28.58 | 38.53 | 51.94 | 43.72 | 51.76 | 50.70 | 44.64 | 33.05 | 30.72 |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 9.14 | 6.97 | 10.17 | 11.86 | 13.00 | 19.82 | 14.47 | 11.92 | 9.09 | 8.29 |
| EV / EBITDA | 32.54 | 31.79 | 40.06 | 37.02 | 33.20 | 36.15 | 56.76 | 44.52 | 41.78 | 29.14 | 25.66 |
| EV / EBIT | 45.11 | 45.12 | 79.45 | 58.52 | 38.55 | 45.97 | 113.80 | 36.16 | 63.66 | 42.95 | 39.10 |
| EV / FCF | — | 42.18 | 33.13 | 49.92 | 62.40 | 51.28 | 59.93 | 69.67 | 54.49 | 39.13 | 36.37 |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 65.8% | 65.8% | 64.8% | 66.4% | 67.7% | 68.4% | 68.0% | 65.4% | 66.3% | 67.2% | 66.5% |
| Operating Margin | 20.7% | 20.7% | 8.4% | 17.8% | 26.3% | 26.8% | 25.5% | 21.3% | 17.6% | 21.2% | 21.6% |
| Net Profit Margin | 15.0% | 15.0% | 6.0% | 14.5% | 25.1% | 24.6% | 15.1% | 31.0% | 13.5% | 19.5% | 13.7% |
| Metric | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 9.0% | 9.0% | 3.7% | 8.3% | 15.6% | 16.6% | 9.5% | 18.0% | 8.6% | 12.3% | 8.4% |
| ROA | 7.1% | 7.1% | 2.8% | 6.3% | 11.6% | 11.9% | 6.5% | 11.7% | 5.5% | 8.0% | 5.8% |
| ROIC | 8.7% | 8.7% | 3.4% | 6.8% | 10.9% | 12.2% | 10.3% | 7.3% | 6.6% | 8.2% | 8.5% |
| ROCE | 10.5% | 10.5% | 4.2% | 8.2% | 12.9% | 14.0% | 11.8% | 8.5% | 7.6% | 9.3% | 9.8% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.13 | 0.13 | 0.23 | 0.20 | 0.23 | 0.19 | 0.27 | 0.31 | 0.43 | 0.31 | 0.37 |
| Debt / EBITDA | 0.78 | 0.78 | 2.09 | 1.32 | 1.12 | 0.82 | 1.29 | 1.81 | 2.48 | 1.69 | 1.92 |
| Net Debt / Equity | — | 0.00 | 0.15 | 0.13 | 0.14 | 0.09 | 0.14 | 0.21 | 0.35 | 0.20 | 0.27 |
| Net Debt / EBITDA | 0.03 | 0.03 | 1.33 | 0.84 | 0.68 | 0.39 | 0.68 | 1.19 | 1.98 | 1.08 | 1.42 |
| Debt / FCF | — | 0.04 | 1.10 | 1.13 | 1.27 | 0.55 | 0.72 | 1.87 | 2.59 | 1.45 | 2.01 |
| Interest Coverage | 45.53 | 45.53 | 12.57 | 12.80 | 31.20 | 27.65 | 11.62 | 15.40 | 6.16 | 13.36 | 16.21 |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 4.55 | 4.55 | 3.46 | 3.87 | 4.84 | 3.44 | 3.35 | 4.88 | 4.05 | 5.06 | 2.55 |
| Quick Ratio | 3.35 | 3.35 | 2.38 | 2.75 | 3.50 | 2.64 | 2.59 | 3.92 | 3.15 | 3.97 | 2.11 |
| Cash Ratio | 1.62 | 1.62 | 0.92 | 0.96 | 1.59 | 1.40 | 1.52 | 2.54 | 1.63 | 2.31 | 1.17 |
| Asset Turnover | — | 0.47 | 0.48 | 0.43 | 0.43 | 0.48 | 0.41 | 0.36 | 0.38 | 0.40 | 0.36 |
| Inventory Turnover | 2.13 | 2.13 | 2.27 | 2.17 | 2.14 | 2.47 | 2.55 | 2.48 | 2.64 | 2.46 | 3.13 |
| Days Sales Outstanding | — | 65.06 | 61.91 | 76.02 | 70.15 | 64.23 | 57.00 | 60.55 | 70.27 | 68.29 | 75.74 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | 0.4% | 0.4% | 0.6% | 0.4% | 0.4% | 0.4% | 0.3% | 0.5% | 0.6% | 0.9% | 1.1% |
| Payout Ratio | 27.4% | 27.4% | 68.7% | 30.0% | 17.6% | 18.4% | 35.3% | 21.3% | 50.3% | 38.3% | 61.2% |
| Metric | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 1.6% | 1.6% | 0.9% | 1.5% | 2.2% | 1.9% | 0.8% | 2.2% | 1.2% | 2.2% | 1.8% |
| FCF Yield | 2.3% | 2.4% | 3.1% | 2.0% | 1.6% | 2.0% | 1.7% | 1.5% | 1.9% | 2.7% | 2.9% |
| Buyback Yield | 0.4% | 0.4% | 3.4% | 0.7% | 0.1% | 1.1% | 0.2% | 0.5% | 0.2% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.8% | 0.8% | 4.0% | 1.1% | 0.5% | 1.5% | 0.5% | 1.0% | 0.8% | 0.9% | 1.1% |
| Shares Outstanding | — | $157M | $160M | $161M | $162M | $164M | $162M | $158M | $156M | $152M | $150M |
Includes 30+ ratios · 30 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying TECH stock.
Bio-Techne Corporation's current P/E ratio is 62.5x. The historical average is 45.6x. This places it at the 83th percentile of its historical range.
Bio-Techne Corporation's current EV/EBITDA is 32.5x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 25.2x.
Bio-Techne Corporation's return on equity (ROE) is 9.0%. The historical average is 17.1%.
Based on historical data, Bio-Techne Corporation is trading at a P/E of 62.5x. This is at the 83th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Bio-Techne Corporation's current dividend yield is 0.44% with a payout ratio of 27.4%.
Bio-Techne Corporation has 65.8% gross margin and 20.7% operating margin. Operating margin above 20% indicates strong pricing power and cost efficiency.
Bio-Techne Corporation's Debt/EBITDA ratio is 0.8x, indicating low leverage. A ratio below 2x is generally considered financially healthy.
Key Metrics
Top Statement Risk
Margin compression from operating cost growth
Metrics are mathematically derived from official filings.
Premium Valuation Amidst Growth Deceleration
Bio-Techne's forward P/E of 35.2x and EV/EBITDA of 23.8x represent a significant premium to peers like Revvity (25.8x), suggesting the market is pricing in a durable moat and a recovery in growth that has yet to materialize in recent quarters.
The valuation multiples appear to be pricing in a re-rating based on the company's high-margin reagent business and potential clinical tailwinds, rather than near-term financial performance. The PEG ratio of 10.53 is exceptionally high, indicating that the current valuation is not supported by the recent deceleration in revenue growth to near-flat levels. This disconnect suggests that any failure to re-accelerate earnings growth could lead to a significant multiple compression.
Gross Margin Strength Masked by Operating Cost Surge
While gross margins have recovered to a healthy 65.8% in 2026Q4, the operating margin of 23.1% remains well below historical norms, indicating that SG&A expenses, which now consume approximately 35% of revenue, are eroding the core profitability of the business.
The wide and persistent gap between gross margin and operating margin suggests that the company's cost structure has become less efficient, potentially due to acquisition integration or a strategic investment phase. This margin compression is the primary headwind to net profitability, as the strong gross margin is not translating into proportional bottom-line earnings. Investors should monitor whether this is a temporary investment cycle or a structural shift in operating leverage.
Low Returns on Capital Despite Fortress Balance Sheet
Despite a debt-to-equity ratio of just 0.14, Bio-Techne's ROIC of 2.6% and ROE of 2.6% in 2026Q4 are exceptionally low, indicating that the company's substantial equity base is not generating commensurate returns for shareholders.
The low return metrics are a direct consequence of the compressed operating margin and the large equity base built through retained earnings. This suggests that the company's capital allocation strategy, while conservative, is currently destroying value by not deploying capital at rates above its cost. The trend shows a recovery from negative returns in 2025Q4, but the current level remains inadequate for a company commanding a premium valuation.
Lengthy Cash Cycle Highlights Working Capital Drag
The cash conversion cycle of 173 days in 2026Q4, driven by a very high days inventory outstanding of 164, indicates that a significant amount of capital is tied up in inventory, which may reflect either strategic stocking or potential inefficiencies in managing biological reagent shelf lives.
The extremely high DIO is a critical metric for a life sciences tools company, as it could signal either a deliberate build-up of key reagents to ensure supply or a risk of obsolescence if demand for specific protein variants shifts. The relatively low DPO of 53 days suggests the company has limited leverage with its suppliers, which, combined with the high inventory levels, creates a working capital drag that suppresses free cash flow generation relative to net income.
The Misleading Signal of the P/E Multiple
The trailing P/E ratio of 62.4x is the most commonly misapplied metric for Bio-Techne, as it is heavily distorted by non-cash acquisition-related charges and does not reflect the underlying cash generation power of the business.
For an M&A-heavy life science tools company, the headline P/E is often inflated by amortization of intangibles and integration costs, making it a poor measure of valuation. A more appropriate metric is the Price/FCF ratio, which at 43.0x is still premium but better reflects the cash the business generates. Analysts should focus on adjusted operating income and free cash flow conversion to assess true earning power, rather than the GAAP net income figure that drives the P/E multiple.